EWM
RXRX icon

Edge Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Edge Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$46K – 89
2026
Q1 		$46K Buy
+15,000
New +$58K 0.01% 85

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IIA
Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Edge Wealth Management's RXRX Position: Q2 2026 in Review

Edge Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 15,000 shares — an estimated $46K sold.

Edge Wealth Management first reported a position in RXRX in Q1 2026 and held it in 1 quarter. The position peaked at $46K in Q1 2026. 24 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Edge Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Edge Wealth Management sold 15,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $46K.
  • Edge Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Edge Wealth Management's Recursion Pharmaceuticals position peaked at $46K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Edge Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.